Saturday, July 4, 2015

Leerink, Canaccord launch coverage of HTG Molecular

Leerink, Canaccord launch coverage of HTG Molecular

June 2, 2015 by · Leave a Comment 

Tweet Analysts at Leerink Partners and Canaccord Genuity have initiated coverage of HTG Molecular Diagnostics (NASDAQ:HTGM) with “outperform” and “buy” ratings, respectively, and price targets of $18 and $17, respectively. The stock closed at $13.91 on Monday. “We believe in the company’s strong and deep management team and strong early relationships with big pharma, biotech, […]

Canaccord starts Neovasc at buy

Canaccord starts Neovasc at buy

April 2, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has launched coverage of Neovasc (NASDAQ:NVCN; TSX:NVC) with a “buy” rating and 12-month target price of $15. The stock closed at $8.99 on Wednesday. Neovasc is one of the early leaders in the burgeoning transcatheter mitral valve replacement (TMVR) space, writes analyst Jason Mills. Its proprietary Tiara valve has demonstrated encouraging results […]

Actinium gearing up for pivotal trial in second half

Actinium gearing up for pivotal trial in second half

March 24, 2015 by · Leave a Comment 

Tweet Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute myeloid leukemia (AML) prior to a bone marrow transplant (BMT). The company also has a second drug candidate, Actimab-A, now in a […]

Canaccord starts Avinger at buy

Canaccord starts Avinger at buy

February 24, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has initiated coverage of Avinger (NASDAQ:AVGR) with a “buy” rating and price target of $18. The stock closed at $10.66 on Monday. “Avinger checks the most important boxes that we look for in a small-cap med-tech growth stock,” writes analyst Jason Mills. He said Avinger targets a large, under-penetrated and growing addressable […]

Transition Therapeutics prices $20-million stock offering

Transition Therapeutics prices $20-million stock offering

February 12, 2015 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has priced a public offering of 3,076,923 common shares at $6.50 each for gross proceeds of $20-million. The company also has granted underwriters a 30-day option to purchase up to an additional 461,538 common shares, which could result in an additional $3-million of gross proceeds. The offering is expected to […]

Neovasc upsizes offering due to market interest

Neovasc upsizes offering due to market interest

January 29, 2015 by · Leave a Comment 

Tweet Due to market interest, Neovasc (NASDAQ:NVCN; TSX:NVC) has increased the size of its previously announced public offering to 10.5 million common shares from eight million shares at a price of $7.19 each for gross proceeds of $63.6-million for the company and $11.9-million for certain directors, officers and employees. The company is selling 8,840,000 of […]

Vital Therapies prices follow-on offering


Vital Therapies prices follow-on offering


October 3, 2014 by · Leave a Comment 

Tweet Vital Therapies (NASDAQ:VTL) has priced a follow-on public offering of two million common shares at a price of $17.50 each and granted underwriters a 30-day option to purchase up to an additional 300,000 shares. BofA Merrill Lynch is acting as sole book-running manager for the offering. William Blair is acting as lead manager and Canaccord […]

Continuum of care to drive future NOVADAQ imaging growth

Continuum of care to drive future NOVADAQ imaging growth

September 9, 2014 by · Leave a Comment 

Tweet NOVADAQ Technologies (NASDAQ:NVDQ; TSX:NDQ), pioneers in fluorescence imaging solutions for the operating room, is now focused on manufacturing and directly marketing and selling imaging solutions for use at multiple points throughout the patient care continuum. “Our continuum of care includes diagnostics that can be performed at outpatient clinics and by primary care physicians, where […]

Canaccord upgrades AngioDynamics to buy

Canaccord upgrades AngioDynamics to buy

June 19, 2014 by · Leave a Comment 

Tweet Canaccord Genuity has upgraded AngioDynamics (NASDAQ:ANGO) to “buy” from “hold” and raised its 12-month price target to $20 from $16.25 after the company received FDA approval for the Celerity tip location system. The stock closed at $15.31 on Wednesday. “We believe improving business trends and strong cash generation will drive growth over the next […]

Stifel, Canaccord start TriVascular Technologies at buy

Stifel, Canaccord start TriVascular Technologies at buy

May 12, 2014 by · Leave a Comment 

Tweet Stifel and Canaccord Genuity have launched coverage of TriVascular Technologies (NASDAQ:TRIV) with “buy” ratings and 12-month price targets of $17 and $20, respectively. The stock closed at $12.92 on Friday. “We see TriVascular as a compelling technology and outsized revenue growth story,” writes Stifel analyst Rick Wise. In his report, Canaccord analyst Jason Mills calls […]

Next Page »

Email Newsletters with Constant Contact
Google+